| Photo credit: Bloomberg |
By Michelle Celarier
When Zafgen, a small Boston biotechnology company, said in late July that it was suspending production of a weight-loss drug that has drawn scrutiny from the Food and Drug Administration for life-threatening side effects, no one could have been happier than Sahm Adrangi, a cocky 35-year-old hedge fund manager who’s in the red...
